12th Annual Women’s Heart & Vascular Symposium

May 6, 2023 | Virtual

Empowering providers to empower women.

Heart and vascular disease remains the leading contributor to morbidity and mortality among both women and men. While the decrease in mortality among women is well documented, the decline still lags behind that of men, with an alarming tendency towards an increased mortality rate among younger women.

Greater life expectancy for women, together with improvements in primary and secondary prevention of cardiovascular disease, will lead to a larger proportion of women living with disease. Substantial sex differences in the burden of different manifestations of cardiovascular disease, including coronary heart disease (CHD), stroke, heart failure, and peripheral artery disease, are widely recognized and must be addressed as new research and best practices are developed.

The latest guidelines, diagnostic strategies & treatment options for women.

New Perspectives, Innovations & Guidelines

Gaps in the prevention and diagnosis of heart and vascular disease in women exist for many reasons. Multiple challenges include recognizing unique symptoms, performing effective diagnostic testing, modifying patients’ lifestyle behaviors, and recognizing that disease may progress differently in women compared to men. Education must continue among the providers who care for women. This video library includes presentations by invited faculty who share insights into current research, guidelines, and outcomes.

Faculty

Cardiology & Echocardiography,
The Texas Heart Institute Center for Cardiovascular Care
Assistant Medical Director,
Director, Center for Women's Heart & Vascular Health
Program Director, Cardiovascular Disease Fellowship
The Texas Heart Institute
Associate Editor, The Texas Heart Institute Journal

Gill Heart & Vascular Institute

Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine

Professor of Medicine, Molecular and Human Genetics, and Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory;
Director, Center for Cardiometabolic Disease Prevention;
Co-Director, Lipid Metabolism and Atherosclerosis Clinic;
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research;
Chief of Cardiovascular Research,
Baylor College of Medicine

Assistant Professor of Surgery
Division of Cardiothoracic Surgery
Assistant Program Director, Education Research
Michael E. DeBakey Department of Surgery
Baylor College of Medicine

Senior Dean of Faculty
Professor Medicine-Cardiology
Mary and Gordon Cain Chair of Internal Medicine in the Winters Center for Heart Failure Research
Medicine-Cardiology
W. A. "Tex" and Deborah Moncrief, Jr. Chair
Medicine-Cardiology
Baylor College of Medicine

Interventional Cardiology, The Texas Heart Institute Center for Cardiovascular Care
Social Media Editor, Texas Heart Institute Journal
Teaching Staff, Interventional Cardiology Subspecialty Fellowship
Teaching Staff, Cardiovascular Disease Fellowship
The Texas Heart Institute

Surgery, The Texas Heart Institute Center for Cardiovascular Care
Teaching Staff, Denton A. Cooley Fellowship, Cardiovascular Surgery Fellowship, and
Thoracic Surgery Residency
The Texas Heart Institute

President, The Texas Heart Institute Center for Cardiovascular Care
Interventional Cardiology, The Texas Heart Institute Center for Cardiovascular Care
Medical Executive Committee, The Texas Heart Institute Professional Staff
Teaching Staff, Cardiovascular Disease Fellowship and Interventional Cardiology Fellowship
The Texas Heart Institute

Cardiologist
Houston Heart

Don W. Chapman, M.D. Endowed Chair of Cardiology
Associate Professor
Medicine-Cardiology
Associate Staff
Cardiology
Cleveland Clinic
Assistant Professor
Medicine Cardiology,
The University of Texas MD Anderson Cancer Center
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine

Teaching Staff, Thoracic Surgery Residency
Physician Ambassador, Center for Women's Heart & Vascular Health
The Texas Heart Institute

Director, Electrophysiology Clinical Research & Innovations
Teaching Staff, Cardiovascular Disease Fellowship, and Clinical Cardiac Electrophysiology Fellowship
The Texas Heart Institute
Editorial Consultant, The Texas Heart Institute Journal

Teaching Staff, Cardiovascular Disease Fellowship and Interventional Cardiology Fellowship
The Texas Heart Institute
Section Editor, The Texas Heart Institute Journal

Agenda

7:50 am     Welcome | Stephanie Coulter, MD, FACC, FASE

8:00           KEYNOTE

Dr. George L. Bakris, MD

Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine

Pillars of therapy in reducing heart failure events and slowing diabetic kidney disease



Session I – Guidelines Updates

2022 Guidelines

9:00 – 9:30       Heart Failure Guidelines | Biykem Bozkurt, MD, PhD

9:30 – 10:00     Aorta Guidelines | Ourania Preventza, MD, MBA, FACS

10:00 – 10:15    Break

2021 Guidelines

10:15 – 10:45    Coronary Artery Disease Guidelines | Briana Costello, MD

10:45 – 11:15     Chest Pain Guidelines | Raymond Stainback, MD, FACC, FASE

11:15 – 12:15      Lunch



Session II – Risk, Assessment & Prevention

12:15 – 12:30    Cardiometabolic Health: Actionable Prevention Strategies and New Care Models | David Aguilar, MD

12:30 – 12:45    Exercise, Fitness and Vascular Disease | Stephanie Coulter, MD, FACC, FASE

12:45 – 1:00     Non-Statin Therapies, Expert ACC Consensus | Christie Ballantyne, MD

1:00 – 1:15        Role of Coronary Calcification and Risk Stratification | Eduardo Hernandez-Vila, MD

1:15 – 1:30         Break



Session III – Treatment Updates

1:30 – 1:45       AS Timing & Intervention | Juan Carlos Plana, MD

1:45 – 2:00      Atrial Fibrillation: New Treatments | Jennifer Cozart, MD

2:00 – 2:15      Role of LAA Exclusion in the Management of Atrial Fibrillation | Mehdi Razavi, MD

2:15 – 2:30       Bypass Grafts in Women: What is the Gold Standard? | Lauren Barron, MD

2:30 – 2:45       To Clip or Not to Clip: The Latest Treatments in Valvular Regurgitation | Pranav Loyalka, MD

2:45 – 3:00 pm     Closing Remarks & Adjourn

CME Information

Educational Objectives

At the conclusion of this activity, the participant should be able to:

  • Describe ways to improve cardiometabolic health by targeting early mechanistic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation).
  • Review various prevention modalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/metabolic procedures
  • Describe a tactical approach of implementing published clinical practice guidelines/algorithms for early behavioral, adiposity, and dysglycemia targeting is emphasized, as well as relevant educational and research implications.
  • Describe the actionable targets for prevention to achieve optimal cardiovascular outcomes in the CMBCD framework.
  • Discuss recent research on cardiorespiratory fitness (CRF) and its impact on all-cause mortality

Purpose

Population-based studies have shown a rise in prevalence of diabetes mellitus, hypertension, dyslipidemia, and obesity in the past three decades. Cardiometabolic health rather than disease represents an important advance for promoting health and health equity. Studies have generally focused on abnormal levels of isolated risk factors, rather than on optimal levels that jointly define health. A new cardiometabolic-based chronic disease (CMBCD) model is emerging and provides a basis for early and sustainable, evidence-based therapeutic targeting to promote cardiometabolic health and mitigate the development and ravages of cardiovascular disease.

Jointly published by the American College of Cardiology (ACC) and American Heart Association (AHA) in November 2022, the new guidelines are intended to support decision-making around diagnosis, screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease. Building upon an earlier version of the document, last updated in 2010, the new guideline incorporates latest evidence to reflect advances in care. Central among the latest additions is a focus on multidisciplinary aortic team care to determine appropriate timing and optimal medical, endovascular and surgical therapies.

The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients’ interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.

 

Accreditation
The Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation
The Texas Heart Institute designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registration Fees

Physicians
$0.00

Non-physician
$0.00

Fellow/Resident/Medical Student
$0.00